Cell cycle profiles and expressions of p21(CIP1) and p27(KIP1) during myocyte development

International Journal of Cardiology

Volumn 67, Issue 2, 1998, Pages 133-142

  Poolman, Robert A ^a   Gilchrist, Ruth ^a   Brooks, Gavin ^a,b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b Prolifix Ltd   (United Kingdom)

Author keywords

Cyclin dependent kinase inhibitor; FACS; Rat

Indexed keywords

CYCLINE; PROTEIN P21; PROTEIN P27;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL MATURATION; CELL PROLIFERATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; HEART MUSCLE CELL; HEART MUSCLE INJURY; MAMMAL; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, MONOCLONAL; CDC2 PROTEIN KINASE; CDC2-CDC28 KINASES; CELL CYCLE; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; CYCLINS; FEMALE; FETUS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HEART; IMMUNOBLOTTING; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MYOCARDIUM; PREGNANCY; PROTEIN-SERINE-THREONINE KINASES; RATS; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEINS;

EID: 0032417616     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(98)00320-9     Document Type: Article

References (62)

1. Claycomb W.C. Control of cardiac muscle cell division. Trends Cardiovasc Med. 2:1992;231-236.
2. McGill C.J., Brooks G. Cell cycle control mechanisms and their role in cardiac growth. Cardiovasc Res. 30:1995;557-569.
3. Li F., Wang X., Capasso J.M., Gerdes A.M. Rapid transition of cardiac myocytes from hyperplasia to hypertrophy during postnatal development. J Mol Cell Cardiol. 28:1996;1737-1746.
4. Brooks G., Poolman R.A., McGill C.J., Li J.-M. Expression and activities of cyclins and cyclin-dependent kinases in developing rat ventricular myocytes. J Mol Cell Cardiol. 29:1997;2261-2271.
5. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature. 371:1994;257-261.
6. Serrano M., Hannon G.J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 366:1993;704-707.
7. Kamb A., Grus N.A., Weaver-Feldhaus J.et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 264:1994;436-440.
8. INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev. 8:1994;2939-2952.
9. Hirai H., Roussel M.F., Kato J.-Y., Ashmun R.A., Sherr C.J. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol. 15:1995;2672-2681.
10. Harper J.W., Adami G.R., Wei N., Keyomarsi K., Elledge S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 75:1993;805-816.
11. Jiang H., Lin J., Fisher P.B. A molecular definition of terminal differentiation in human melanoma cells. Mol Cell Differentiat. 2:1994;221-239.
12. Polyak K., Kato J.-Y., Solomon M.J.et al. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev. 8:1994;9-22.
13. Toyoshima H., Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell. 78:1994;67-74.
14. KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev. 9:1995;639-649.
15. CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev. 9:1995;650-662.
16. ink4 requires functional retinoblastoma protein. Proc Natl Acad Sci USA. 92:1995;6289-6293.
17. Harper J.W., Elledge S.J., Ketomarsi K.et al. Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell. 6:1995;387-400.
18. Capasso J.M., Bruno S., Cheng W.et al. Ventricular loading is coupled with DNA synthesis in adult cardiac myocytes after acute and chronic myocardial infarction in rats. Circ Res. 71:1992;1379-1389.
19. Li J.-M., Brooks G. Down-regulation of the cyclin dependent kinase inhibitors, p21 and p27, in pressure overload hypertrophy. Am J Physiol. 273:1997;H1358-H1367.
20. Draetta G., Brizuels L., Potashkin J., Beach D. Identification of p34 and p13, human homologs of the cell-cycle regulators of fission yeast encoded by CDC2 and SUC1. Cell. 50:1987;319-325.
21. Guo K., Wang J., Andres V., Smith R.C., Walsh K. MyoD-induced expression of p21 inhibits cyclin-dependent kinase activity upon myocyte terminal differentiation. Mol Cell Biol. 15:1995;3823-3829.
22. Bradford M.M. A rapid and sensitive method for the quatitation of microgram quantities of protein utilising the principle of protein-dye binding. Anal Biochem. 72:1976;248-254.
23. Marino T.A., Haldar S., Williamson E.C.et al. Proliferating cell nuclear antigen in developing and adult rat cardiac muscle cells. Circ Res. 69:1991;1353-1360.
24. Horky M., Kuchtickova S., Vojtesek B., Kolar F. Induction of cell-cycle inhibitor p21 in rat ventricular myocytes during early postnatal transition from hyperplasia to hypertrophy. Physiol Res. 46:1997;233-235.
25. Burton P.B.J., Yacoub M.H., Barton P.J.R. Cell cycle regulatory molecule expression during heart development. J Mol Cell Cardiol. 29:1997;A41.
26. KIP1, in rat hearts during development. J Mol Cell Cardiol. 30:1998;463-474.
27. Flink I.L., Oana S., Maitra N., Bahl J.J., Morkin E. Changes in E2F complexes containing retinoblastoma protein family members and increased cyclin-dependent kinase inhibitor activities during terminal differentiation of cardiomyocytes. J Mol Cell Cardiol. 30:1998;563-578.
28. McGill C.J., Poolman R.A., Brooks G. Expression of cell cycle molecules during development of rat cardiac myocytes. J Mol Cell Cardiol. 28:1996;A76.
29. Poolman R.A., Brooks G. Expression of CIP/KIP family of cyclin-dependent kinase inhibitors during cardiac development. Circulation. 94:1996;A0909.
30. Kang M.J., Kim J.-S., Chae S.-W., Koh K.N., Koh G.Y. Cyclins and cyclin dependent kinases during cardiac development. Mol Cells. 7:1997;360-366.
31. Kang M.J., Koh G.Y. Differential and dramatic changes of cyclin-dependent kinase activities in cardiomyocytes during the neonatal period. J Mol Cell Cardiol. 29:1997;1767-1777.
32. Dulic V., Kaufmann W.K., Wilson S.J.et al. p53-Dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell. 76:1994;1013-1023.
33. Zhu X., Ohtsubo M., Bohmer R.M., Roberts J.M., Assoian R.K. Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2 and phosphorylation of the retinoblastoma protein. J Cell Biol. 133:1996;391-403.
34. waf1 pathway in response to disruption of cell-matrix interactions. JBC. 272:1997;29091-29098.
35. Li J.-M., Poolman R.A., Brooks G. Role of G1 phase cyclins and cyclin-dependent kinases during cardiomyocyte hypertrophic growth in rats. Am J Physiol. 275:1998;H814-H822.
36. KIP1 blocks cyclin E-dependent transactivation of cyclin A gene expression. Mol Cell Biol. 17:1997;407-415.
37. Yoshizumi M., Lee W.-S., Hsieh C.-M.et al. Disappearance of cyclin A correlates with permanent withdrawal of cardiomyocytes from the cell cycle in human and rat hearts. J Clin Invest. 95:1995;2275-2280.
38. Dimri G.P., Nakanishi M., Desprez P.-Y., Smith J.R., Campisi J. Inhibition of E2F activity by the cyclin-dependent protein kinase inhibitor p21 in cells expressing or lacking a functional retinoblastoma protein. Mol Cell Biol. 16:1996;2987-2997.
39. Waga S., Hannon G.L., Beach D., Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature. 369:1994;574-578.
40. Zhang H., Hannon G.J., Beach D. p21-Containing cyclin kinases exist in both active and inactive states. Genes Dev. 8:1994;1750-1758.
41. LaBaer J., Garrett M.D., Stevenson L.F.et al. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 11:1997;847-862.
42. Kip1 with cyclin A-Cdk2 and cyclin D2-Cdk4. JBC. 272:1997;25863-25872.
43. Cip1 in muscle and other terminally differentiating cells. Science. 267:1995;1024-1027.
44. Schneider J.W., Gu W., Zhu L., Mahdavi V., Nadal-Ginard B. Reversal of terminal differentiation mediated by p107 in Rb-/-muscle cells. Science. 264:1994;1467-1471.
45. Deng C., Zhang P., Harper J.W., Elledge S.J., Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell. 82:1995;675-684.
46. Nakayama K., Ishida N., Shirane M.et al. Mice lacking p27 display increased body size, multiple organ hyperplasia, retinal dysplasia and pituitary tumours. Cell. 85:1996;707-720.
47. Fero M.L., Rivkin M., Tasch M.et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis and female sterility in p27-deficient mice. Cell. 85:1996;733-744.
48. Kiyokawa H., Kineman R.D., Manova-Tadorova K.O.et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27. Cell. 85:1996;721-732.
49. Agah R., Kirschenbaum L.A., Abdellatif M.et al. Adenoviral delivery of E2F-1 directs cell cycle reentry and p53-independent apoptosis in postmitotic adult myocardium in vivo. J Clin Invest. 100:1997;2722-2728.
50. Kirschenbaum L.A., Abdellatif M., Chakraborty S., Schneider M.D. Human E2F-1 reactivates cell cycle progression in ventricular myocytes and represses cardiac gene transcription. Dev Biol. 179:1996;402-411.
51. Soonpaa M.H., Koh G.Y., Pajak L.et al. Cyclin D1 overexpression promotes cardiomyocyte DNA synthesis and multinucleation in transgenic mice. J Clin Invest. 99:1997;2644-2654.
52. Soonpaa M.H., Koh G.Y., Klug M.G., Field L.J. Formation of nascent intercalated disks between grafted fetal cardiomyocytes and host myocardium. Science. 264:1994;98-101.
53. Leor J., Patterson M., Quinones M.J., Kedes L.H., Kloner R.A. Transplantation of fetal myocardial tissue into the infarcted myocardium of rat. Circulation. 94:1996;II332-336.
54. Scorsin M., Marotte F., Sabri A.et al. Can grafted cardiomyocytes colonize peri-infarct myocardial areas? Circulation. 94:1996;II337-340.
55. Tam S.K.C., Gu W., Nadal-Ginard B. Molecular cardiomyoplasty: potential cardiac gene therapy for chronic heart failure. J Thorac Cardiovasc Surg. 109:1995;918-924.
56. Murry C.E., Kay M.A., Bartosek T., Hauschka S.D., Schwartz S.M. Muscle differentiation during repair of myocardial necrosis in rats via gene transfer with MyoD. J Clin Invest. 98:1996;2209-2217.
57. Prentice H., Kloner R.A., Sartorelli V., Bellows S.D., Alker K., Kedes L. Transformation of cardiac fibroblasts into the skeletal muscle phenotype by injection of a MyoD-expressing retrovirus into ischaemic heart. Circulation. 88:1993;I475.
58. Sassoon D., Lyons G., Wright W.E.et al. Expression of two myogenic regulatory factors myogenin and MyoD1 during mouse embryogenesis. Nature. 341:1989;303-307.
59. Leor J., Quinones M.J., Patterson M., Kedes L., Kloner R.A. Adenovirus-mediated gene transfer into infarcted myocardium: feasibility, timing and location of expression. J Mol Cell Cardiol. 28:1996;2057-2067.
60. Wright M.J., Wightman L., Lilley C.et al. Investigation of myocardial gene transfer comparison of vectors and models. J Mol Cell Cardiol. 30:1998;A48.
61. Wright M.J., Rosenthal E., Stewart L.et al. In vivo gene transfer appearances are deceptive. J Mol Cell Cardiol. 30:1998;A48.
62. Aoki M., Morishita R., Muraishi A.et al. Efficient in vivo gene transfer into the heart in the rat myocardial infarction model using the HVJ (hemagglutinating virus of Japan)-liposome method. J Mol Cell Cardiol. 29:1997;949-959.